biotx

Executive Summary

biotx is a Munich-based AI/ML biotech company leveraging large-scale Mendelian randomization and colocalization to systematically test every gene across all human tissues. By analyzing billions of causal data points linking genes to thousands of diseases and biomarkers, biotx aims to identify high-confidence therapeutic targets. The company's platform generates unbiased, genome-wide causal evidence, which could significantly de-risk drug development and enable precision medicine. Currently at Phase 2 stage, biotx is advancing its proprietary database and seeking partnerships to validate its targets in preclinical and clinical settings. The unique approach of combining genetic epidemiology with machine learning positions biotx to accelerate target discovery across a wide range of indications, though the company has not yet disclosed specific drug candidates or clinical pipelines. With a strong scientific foundation and a scalable data-driven platform, biotx represents a high-potential investment opportunity in the AI-driven drug discovery space.

Upcoming Catalysts (preview)

• Q4 2026Major partnership with a pharmaceutical company for target validation60% success
• Q3 2026Publication of platform validation data in a peer-reviewed journal80% success
• Q1 2027Series B funding round to scale platform and build internal pipeline50% success